198 related articles for article (PubMed ID: 21360443)
21. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma.
Abdulrauf SI; Edvardsen K; Ho KL; Yang XY; Rock JP; Rosenblum ML
J Neurosurg; 1998 Mar; 88(3):513-20. PubMed ID: 9488306
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival.
Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S
Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536
[TBL] [Abstract][Full Text] [Related]
23. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas.
Barresi V; Cerasoli S; Vitarelli E; Tuccari G
Acta Neuropathol; 2007 Aug; 114(2):147-56. PubMed ID: 17594108
[TBL] [Abstract][Full Text] [Related]
24. Expression of tenascin-C in astrocytic tumors: its relevance to proliferation and angiogenesis.
Kim CH; Bak KH; Kim YS; Kim JM; Ko Y; Oh SJ; Kim KM; Hong EK
Surg Neurol; 2000 Sep; 54(3):235-40. PubMed ID: 11118570
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: correlation with IL-6, VEGF and microvessel morphometry.
Piperi C; Samaras V; Levidou G; Kavantzas N; Boviatsis E; Petraki K; Grivas A; Barbatis C; Varsos V; Patsouris E; Korkolopoulou P
Cytokine; 2011 Sep; 55(3):387-95. PubMed ID: 21684758
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of vascular adhesion protein-1 is associated with poor prognosis of astrocytomas.
Kostoro J; Chang SJ; Clark Lai YC; Wu CC; Chai CY; Kwan AL
APMIS; 2016 Jun; 124(6):462-8. PubMed ID: 26935340
[TBL] [Abstract][Full Text] [Related]
27. High CHI3L1 expression is associated with glioma patient survival.
Steponaitis G; Skiriutė D; Kazlauskas A; Golubickaitė I; Stakaitis R; Tamašauskas A; Vaitkienė P
Diagn Pathol; 2016 Apr; 11():42. PubMed ID: 27121858
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas.
Calatozzolo C; Maderna E; Pollo B; Gelati M; Marras C; Silvani A; Croci D; Boiardi A; Salmaggi A
Cancer Biol Ther; 2006 Jul; 5(7):827-32. PubMed ID: 16760646
[TBL] [Abstract][Full Text] [Related]
29. Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood.
Gesundheit B; Klement G; Senger C; Kerbel R; Kieran M; Baruchel S; Becker L
Med Pediatr Oncol; 2003 Dec; 41(6):516-26. PubMed ID: 14595708
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.
Netto GC; Bleil CB; Hilbig A; Coutinho LM
Neuropathology; 2008 Feb; 28(1):17-23. PubMed ID: 18181830
[TBL] [Abstract][Full Text] [Related]
31. Tenascin expression in astrocytomas correlates with angiogenesis.
Zagzag D; Friedlander DR; Miller DC; Dosik J; Cangiarella J; Kostianovsky M; Cohen H; Grumet M; Greco MA
Cancer Res; 1995 Feb; 55(4):907-14. PubMed ID: 7531617
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
[TBL] [Abstract][Full Text] [Related]
33. Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas.
Ramachandran RK; Sørensen MD; Aaberg-Jessen C; Hermansen SK; Kristensen BW
PLoS One; 2017; 12(2):e0172234. PubMed ID: 28234925
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor?
Oehring RD; Miletic M; Valter MM; Pietsch T; Neumann J; Fimmers R; Schlegel U
J Neurooncol; 1999; 45(2):117-25. PubMed ID: 10778727
[TBL] [Abstract][Full Text] [Related]
35. Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors.
Peles E; Lidar Z; Simon AJ; Grossman R; Nass D; Ram Z
Neurosurgery; 2004 Sep; 55(3):562-7; discussion 567-8. PubMed ID: 15335423
[TBL] [Abstract][Full Text] [Related]
36. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
37. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
38. Expression and Prognostic Value of Oct-4 in Astrocytic Brain Tumors.
Krogh Petersen J; Jensen P; Dahl Sørensen M; Winther Kristensen B
PLoS One; 2016; 11(12):e0169129. PubMed ID: 28030635
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies.
Torp SH
Clin Neuropathol; 2002; 21(6):252-7. PubMed ID: 12489673
[TBL] [Abstract][Full Text] [Related]
40. Algorithm for the standardized assessment of vascular patterns in glioblastoma specimens.
Preusser M; Birner P; Hainfellner JA
Clin Neuropathol; 2004; 23(5):238-40. PubMed ID: 15581027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
